fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Clarithromycin

All products: general benefit

Biaxin XL · DIN 02244756 · 500 mg · extended release tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-16 — choose a marketed DIN from the same-category list.Discontinued September 16, 2020 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-16 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-09-16 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Biaxin XL · DIN 02244756 Manufacturer: BGP Pharma ULC; listing date 2003-01-30 Daily cost (source): $5.1344 Health Canada: Cancelled post market since 2020-09-16 · brand BIAXIN XL · ATC J01FA09 CLARITHROMYCIN · form Tablet (extended-release) · route Oral · ingredients CLARITHROMYCIN 500 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); live check failed, extract retained: Health Canada DPD page The read operation timed out · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244756)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02244756). DIN 02244756: Biaxin XL Raw flags: dinStatus=E, sec3=Y Item: 081212032; group id 21; item number 0032; lccId None; manufacturer id BGP Source form: ER Tab; strength: 500mg Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $2.5672; ministry $1.2572 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244756 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); live check failed, extract retained: https://health-products.canada.ca/api/drug/drugproduct/?din=02244756&lang=en&type=json: The read operation timed out · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68745
Interchangeable products
Act Clarithromycin XL · DIN 02403196 · $1.2572 Apo-Clarithromycin XL · DIN 02413345 · $1.2572
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since September 16, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01FA): coverage varies; not interchangeable

  • Azithromycin (Zithromax): general benefit, limited Use 549, not a benefit
  • Erythromycin base (Erythromid): general benefit, not a benefit
  • Erythromycin estolate (Ilosone): general benefit, not a benefit
  • Erythromycin ethylsuccinate (Ees-200): general benefit, not a benefit
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered

Matched class: 08:12:12 Erythromycins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): AZITHROMYCIN, ERYTHROMYCIN BASE, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE 08:12:12 Erythromycins

AZITHROMYCIN

· 28 products · Listed, not a benefit (6), General benefit (21), Limited Use, codes 549 (1) · strengths: 100mg/5mL, 200mg/5mL, 250mg, 600mg · O/L-15mL Pk, O/L-22.5mL Pk, O/L-37.5mL Pk, Tab

ERYTHROMYCIN BASE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ERYTHROMYCIN ESTOLATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg/mL · O/L

ERYTHROMYCIN ETHYLSUCCINATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg/mL, 80mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:12
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CIPROFLOXACIN AND DEXAMETHASONE · Limited Use, codes 509 INDICATIONS AND CLINICAL USE CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of infections caused by most strains of the designated microorganisms in the specific conditions listed below: Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6 months of age due to: Aerobic, Gram-Positive: Streptococcus pneumoniae Staphylococcus aureus Aerobic, Gram-Negative: Haemophilus influenza Moraxella catarrhalis Pseudomonas aeruginosa Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to: Aerobic, Gram-Positive: Staphylococcus aureus Aerobic, Gram-Negative: Pseudomonas aeruginosa To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. PM: https://pdf.hres.ca/dpd_pm/00041611.PDF; date September 27, 2017; DIN 02252716; fetched 2026-09-10 Product monograph TETRACYCLINE · Listed, not a benefit (1), General benefit (1) Indications TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following microorganisms: • Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis, agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis). PM: https://pdf.hres.ca/dpd_pm/00084169.PDF; date 2026-03-17; DIN 00580929; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS BIAXIN BID® (clarithromycin tablets USP, film-coated) BIAXIN BID® may be indicated in the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the diseases listed below: • Upper Respiratory Tract • Pharyngiitis/tonsillitis, caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). • Acute maxillary sinusitis caused by Streptococcus pneumoniae (S. pneumoniae), Haemophilus influenzae (H. influenzae), and Moraxella (Branhamella) catarrhalis [M. (Branhamella) catarrhalis]. • Lower Respiratory Tract • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (including beta-lactamase producing strains), M. (Branhamella) catarrhalis (including beta- lactamase producing strains). • Pneumonia caused by S. pneumoniae and Mycoplasma. pneumoniae (M. pneumoniae). See WARNINGS AND PRECAUTIONS, Susceptibility/Resistance. • Uncomplicated Skin and Skin Structure Infections • Uncomplicated Skin and Skin Structure Infections caused by Streptococcus pyogenes (S. pyogenes), Staphylococcus aureus… https://pdf.hres.ca/dpd_pm/00078094.PDF PM date: DEC 17, 2024 Source product: BIAXIN BID; DIN 01984853; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18